Harvard Perspectives on Prostate Disease

Using PSA to determine prognosis

An interview with renowned radiation oncologist and researcher Anthony D'Amico, M.D., Ph.D.

The 186,000 or so men likely to be diagnosed with prostate cancer in the United States this year will face a myriad of choices and ask countless questions. "Am I going to die of this disease?" is likely the most frequent query. Until relatively recently, this question was nearly impossible to answer. After all, it wasn't until the late 1980s that testing for prostate-specific antigen (PSA) began; before that, most prostate tumors were detected during a digital rectal examination (DRE), when they were advanced enough to be felt through the rectal wall.

To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »